APO Research
Talk to an analyst

APO RESEARCH · REPORT

Bevacizumab Injection

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Bevacizumab Injection Industry Growth and Trends Forecast to 2032

2 January 2026100 pages

Choose your research edition.

Industry ResearchBevacizumab Injection Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Bevacizumab Injection Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Bevacizumab Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Bevacizumab Injection Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Bevacizumab Injection Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Bevacizumab Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Bevacizumab Injection include Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero Group, Samsung Bioepis, Amgen and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Bevacizumab Injection market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Bevacizumab Injection market size, estimates, and forecasts are presented in terms of sales volume (K Doses) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Bevacizumab Injection market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Bevacizumab Injection.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Bevacizumab Injection market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Bevacizumab Injection Market by Company

Biocon

Cadila Pharmaceuticals

Centus

Dr Reddy's

Genentech

Hetero Group

Samsung Bioepis

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Mylan

Bevacizumab Injection Segment by Type

100mg

400mg

Bevacizumab Injection Segment by Application

Age-related macular degeneration (AMD)

Ovarian Cancer

Others

Bevacizumab Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Bevacizumab Injection manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Bevacizumab Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 100mg Table 2. Major Company of 400mg Table 3. Global Bevacizumab Injection Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Bevacizumab Injection Sales by Type (2021-2026) & (K Doses) Table 5. Global Bevacizumab Injection Sales Market Share in Volume by Type (2021-2026) Table 6. Global Bevacizumab Injection Sales by Type (2021-2026) & (US$ Million) Table 7. Global Bevacizumab Injection Sales Market Share in Value by Type (2021-2026) Table 8. Global Bevacizumab Injection Price by Type (2021-2026) & (US$/Dose) Table 9. Global Bevacizumab Injection Sales by Type (2027-2032) & (K Doses) Table 10. Global Bevacizumab Injection Sales Market Share in Volume by Type (2027-2032) Table 11. Global Bevacizumab Injection Sales by Type (2027-2032) & (US$ Million) Table 12. Global Bevacizumab Injection Sales Market Share in Value by Type (2027-2032) Table 13. Global Bevacizumab Injection Price by Type (2027-2032) & (US$/Dose) Table 14. North America Bevacizumab Injection Sales by Type (2021-2026) & (K Doses) Table 15. North America Bevacizumab Injection Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Bevacizumab Injection Sales by Type (2021-2026) & (K Doses) Table 17. Europe Bevacizumab Injection Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Bevacizumab Injection Sales by Type (2021-2026) & (K Doses) Table 19. Asia-Pacific Bevacizumab Injection Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Bevacizumab Injection Sales by Type (2021-2026) & (K Doses) Table 21. Latin America Bevacizumab Injection Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Bevacizumab Injection Sales by Type (2021-2026) & (K Doses) Table 23. Middle East and Africa Bevacizumab Injection Sales by Type (2021-2026) & (US$ Million) Table 24. Bevacizumab Injection Industry Trends Table 25. Bevacizumab Injection Industry Drivers Table 26. Bevacizumab Injection Industry Opportunities and Challenges Table 27. Bevacizumab Injection Industry Restraints Table 28. Global Bevacizumab Injection Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Bevacizumab Injection Revenue Market Share by Company (2021-2026) Table 30. Global Bevacizumab Injection Sales by Company (2021-2026) & (K Doses) Table 31. Global Bevacizumab Injection Sales Share by Company (2021-2026) Table 32. Global Bevacizumab Injection Market Price by Company (2021-2026) & (US$/Dose) Table 33. Global Bevacizumab Injection Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Bevacizumab Injection Major Company Production Sites and Headquarters Table 35. Global Bevacizumab Injection Company, Product Type & Application Table 36. Global Bevacizumab Injection Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Bevacizumab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Bevacizumab Injection Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Bevacizumab Injection Sales by Region (2021-2026) & (K Doses) Table 41. Global Bevacizumab Injection Sales Market Share in Volume by Region (2021-2026) Table 42. Global Bevacizumab Injection Sales by Region (2021-2026) & (US$ Million) Table 43. Global Bevacizumab Injection Sales Market Share in Value by Region (2021-2026) Table 44. Global Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 45. Global Bevacizumab Injection Sales by Region (2027-2032) & (K Doses) Table 46. Global Bevacizumab Injection Sales Market Share in Volume by Region (2027-2032) Table 47. Global Bevacizumab Injection Sales by Region (2027-2032) & (US$ Million) Table 48. Global Bevacizumab Injection Sales Market Share in Value by Region (2027-2032) Table 49. Global Bevacizumab Injection Sales (K Doses), Value (US$ Million), Price (US$/Dose) and Gross Margin (2027-2032) Table 50. Global Bevacizumab Injection Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Bevacizumab Injection Sales by Application (2021-2026) & (K Doses) Table 52. Global Bevacizumab Injection Sales Market Share in Volume by Application (2021-2026) Table 53. Global Bevacizumab Injection Sales by Application (2021-2026) & (US$ Million) Table 54. Global Bevacizumab Injection Sales Market Share in Value by Application (2021-2026) Table 55. Global Bevacizumab Injection Price by Application (2021-2026) & (US$/Dose) Table 56. Global Bevacizumab Injection Sales by Application (2027-2032) & (K Doses) Table 57. Global Bevacizumab Injection Sales Market Share in Volume by Application (2027-2032) Table 58. Global Bevacizumab Injection Sales by Application (2027-2032) & (US$ Million) Table 59. Global Bevacizumab Injection Sales Market Share in Value by Application (2027-2032) Table 60. Global Bevacizumab Injection Price by Application (2027-2032) & (US$/Dose) Table 61. North America Bevacizumab Injection Sales by Application (2021-2026) & (K Doses) Table 62. North America Bevacizumab Injection Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Bevacizumab Injection Sales by Application (2021-2026) & (K Doses) Table 64. Europe Bevacizumab Injection Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Bevacizumab Injection Sales by Application (2021-2026) & (K Doses) Table 66. Asia-Pacific Bevacizumab Injection Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Bevacizumab Injection Sales by Application (2021-2026) & (K Doses) Table 68. Latin America Bevacizumab Injection Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Bevacizumab Injection Sales by Application (2021-2026) & (K Doses) Table 70. Middle East and Africa Bevacizumab Injection Sales by Application (2021-2026) & (US$ Million) Table 71. Biocon Company Information Table 72. Biocon Business Overview Table 73. Biocon Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 74. Biocon Bevacizumab Injection Product Portfolio Table 75. Biocon Recent Development Table 76. Cadila Pharmaceuticals Company Information Table 77. Cadila Pharmaceuticals Business Overview Table 78. Cadila Pharmaceuticals Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 79. Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio Table 80. Cadila Pharmaceuticals Recent Development Table 81. Centus Company Information Table 82. Centus Business Overview Table 83. Centus Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 84. Centus Bevacizumab Injection Product Portfolio Table 85. Centus Recent Development Table 86. Dr Reddy's Company Information Table 87. Dr Reddy's Business Overview Table 88. Dr Reddy's Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 89. Dr Reddy's Bevacizumab Injection Product Portfolio Table 90. Dr Reddy's Recent Development Table 91. Genentech Company Information Table 92. Genentech Business Overview Table 93. Genentech Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 94. Genentech Bevacizumab Injection Product Portfolio Table 95. Genentech Recent Development Table 96. Hetero Group Company Information Table 97. Hetero Group Business Overview Table 98. Hetero Group Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 99. Hetero Group Bevacizumab Injection Product Portfolio Table 100. Hetero Group Recent Development Table 101. Samsung Bioepis Company Information Table 102. Samsung Bioepis Business Overview Table 103. Samsung Bioepis Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 104. Samsung Bioepis Bevacizumab Injection Product Portfolio Table 105. Samsung Bioepis Recent Development Table 106. Amgen Company Information Table 107. Amgen Business Overview Table 108. Amgen Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 109. Amgen Bevacizumab Injection Product Portfolio Table 110. Amgen Recent Development Table 111. Bayer Company Information Table 112. Bayer Business Overview Table 113. Bayer Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 114. Bayer Bevacizumab Injection Product Portfolio Table 115. Bayer Recent Development Table 116. Pfizer Company Information Table 117. Pfizer Business Overview Table 118. Pfizer Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 119. Pfizer Bevacizumab Injection Product Portfolio Table 120. Pfizer Recent Development Table 121. Eli Lilly Company Information Table 122. Eli Lilly Business Overview Table 123. Eli Lilly Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 124. Eli Lilly Bevacizumab Injection Product Portfolio Table 125. Eli Lilly Recent Development Table 126. Roche Company Information Table 127. Roche Business Overview Table 128. Roche Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 129. Roche Bevacizumab Injection Product Portfolio Table 130. Roche Recent Development Table 131. Mylan Company Information Table 132. Mylan Business Overview Table 133. Mylan Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 134. Mylan Bevacizumab Injection Product Portfolio Table 135. Mylan Recent Development Table 136. North America Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 137. North America Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 138. North America Bevacizumab Injection Sales Market Share by Country (2021-2026) Table 139. North America Bevacizumab Injection Sales Forecast by Country (2027-2032) & (K Doses) Table 140. North America Bevacizumab Injection Sales Market Share Forecast by Country (2027-2032) Table 141. North America Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. North America Bevacizumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 143. North America Bevacizumab Injection Market Share by Country (2021-2026) Table 144. North America Bevacizumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. North America Bevacizumab Injection Market Share Forecast by Country (2027-2032) Table 146. Europe Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 147. Europe Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 148. Europe Bevacizumab Injection Sales Market Share by Country (2021-2026) Table 149. Europe Bevacizumab Injection Sales Forecast by Country (2027-2032) & (K Doses) Table 150. Europe Bevacizumab Injection Sales Market Share Forecast by Country (2027-2032) Table 151. Europe Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Europe Bevacizumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 153. Europe Bevacizumab Injection Market Share by Country (2021-2026) Table 154. Europe Bevacizumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Europe Bevacizumab Injection Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 158. Asia-Pacific Bevacizumab Injection Sales Market Share by Country (2021-2026) Table 159. Asia-Pacific Bevacizumab Injection Sales Forecast by Country (2027-2032) & (K Doses) Table 160. Asia-Pacific Bevacizumab Injection Sales Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Bevacizumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 163. Asia-Pacific Bevacizumab Injection Market Share by Country (2021-2026) Table 164. Asia-Pacific Bevacizumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Asia-Pacific Bevacizumab Injection Market Share Forecast by Country (2027-2032) Table 166. Latin America Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 167. Latin America Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 168. Latin America Bevacizumab Injection Sales Market Share by Country (2021-2026) Table 169. Latin America Bevacizumab Injection Sales Forecast by Country (2027-2032) & (K Doses) Table 170. Latin America Bevacizumab Injection Sales Market Share Forecast by Country (2027-2032) Table 171. Latin America Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Latin America Bevacizumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 173. Latin America Bevacizumab Injection Market Share by Country (2021-2026) Table 174. Latin America Bevacizumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Latin America Bevacizumab Injection Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (K Doses): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Bevacizumab Injection Sales by Country (2021-2026) & (K Doses) Table 178. Middle East and Africa Bevacizumab Injection Sales Market Share by Country (2021-2026) Table 179. Middle East and Africa Bevacizumab Injection Sales Forecast by Country (2027-2032) & (K Doses) Table 180. Middle East and Africa Bevacizumab Injection Sales Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Bevacizumab Injection Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Bevacizumab Injection Market Size by Country (2021-2026) & (US$ Million) Table 183. Middle East and Africa Bevacizumab Injection Market Share by Country (2021-2026) Table 184. Middle East and Africa Bevacizumab Injection Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Middle East and Africa Bevacizumab Injection Market Share Forecast by Country (2027-2032) Table 186. Key Raw Materials Table 187. Raw Materials Key Suppliers Table 188. Bevacizumab Injection Distributors List Table 189. Bevacizumab Injection Customers List Table 190. Research Programs/Design for This Report Table 191. Authors List of This Report Table 192. Secondary Sources Table 193. Primary Sources List of Figures Figure 1. Bevacizumab Injection Image Figure 2. Global Bevacizumab Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Bevacizumab Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global Bevacizumab Injection Sales (2021-2032) & (K Doses) Figure 5. 100mg Image Figure 6. Global 100mg Sales YoY Growth (2021-2032) & (K Doses) Figure 7. 400mg Image Figure 8. Global 400mg Sales YoY Growth (2021-2032) & (K Doses) Figure 9. Global Bevacizumab Injection Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Bevacizumab Injection Market Share by Type 2025 VS 2032 Figure 11. North America Bevacizumab Injection Sales Market Share in Volume by Type in 2025 Figure 12. North America Bevacizumab Injection Sales Market Share in Value by Type in 2025 Figure 13. Europe Bevacizumab Injection Sales Market Share in Volume by Type in 2025 Figure 14. Europe Bevacizumab Injection Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Bevacizumab Injection Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Bevacizumab Injection Sales Market Share in Value by Type in 2025 Figure 17. Latin America Bevacizumab Injection Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Bevacizumab Injection Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Bevacizumab Injection Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Bevacizumab Injection Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Bevacizumab Injection Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Age-related macular degeneration (AMD) Image Figure 24. Global Age-related macular degeneration (AMD) Sales YoY Growth (2021-2032) & (K Doses) Figure 25. Ovarian Cancer Image Figure 26. Global Ovarian Cancer Sales YoY Growth (2021-2032) & (K Doses) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (K Doses) Figure 29. Global Bevacizumab Injection Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Bevacizumab Injection Market Share by Application 2025 VS 2032 Figure 31. North America Bevacizumab Injection Sales Market Share in Volume by Application in 2025 Figure 32. North America Bevacizumab Injection Sales Market Share in Value by Application in 2025 Figure 33. Europe Bevacizumab Injection Sales Market Share in Volume by Application in 2025 Figure 34. Europe Bevacizumab Injection Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Bevacizumab Injection Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Bevacizumab Injection Sales Market Share in Value by Application in 2025 Figure 37. Latin America Bevacizumab Injection Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Bevacizumab Injection Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Bevacizumab Injection Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Bevacizumab Injection Sales Market Share in Value by Application in 2025 Figure 41. North America Bevacizumab Injection Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 42. North America Bevacizumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Bevacizumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Bevacizumab Injection Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 46. Europe Bevacizumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Bevacizumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Bevacizumab Injection Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 50. Asia-Pacific Bevacizumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Bevacizumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Bevacizumab Injection Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 54. Latin America Bevacizumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Bevacizumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Bevacizumab Injection Sales by Country: 2021 VS 2025 VS 2032 (K Doses) Figure 58. Middle East and Africa Bevacizumab Injection Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Bevacizumab Injection Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Bevacizumab Injection Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Bevacizumab Injection Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • 100mg
  • 400mg
Applications
  • Age-related macular degeneration (AMD)
  • Ovarian Cancer
  • Others
Companies covered
  • Biocon
  • Cadila Pharmaceuticals
  • Centus
  • Dr Reddy's
  • Genentech
  • Hetero Group
  • Samsung Bioepis
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Mylan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Bevacizumab Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Bevacizumab Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Bevacizumab Injection Market by Type
  6. 1.3.1 100mg
  7. 1.3.2 400mg
  8. 1.4 Global Bevacizumab Injection Market Size by Type
  9. 1.4.1 Global Bevacizumab Injection Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Bevacizumab Injection Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Bevacizumab Injection Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Bevacizumab Injection Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Bevacizumab Injection Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Bevacizumab Injection Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Bevacizumab Injection Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Bevacizumab Injection Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Bevacizumab Injection Industry Trends
  2. 2.2 Bevacizumab Injection Industry Drivers
  3. 2.3 Bevacizumab Injection Industry Opportunities and Challenges
  4. 2.4 Bevacizumab Injection Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Bevacizumab Injection Revenue (2021-2026)
  2. 3.2 Global Top Players by Bevacizumab Injection Sales (2021-2026)
  3. 3.3 Global Top Players by Bevacizumab Injection Price (2021-2026)
  4. 3.4 Global Bevacizumab Injection Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Bevacizumab Injection Major Company Production Sites & Headquarters
  6. 3.6 Global Bevacizumab Injection Company, Product Type & Application
  7. 3.7 Global Bevacizumab Injection Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Bevacizumab Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Bevacizumab Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Bevacizumab Injection Tier 1, Tier 2, and Tier 3
4 Bevacizumab Injection Regional Status and Outlook
  1. 4.1 Global Bevacizumab Injection Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Bevacizumab Injection Historic Market Size by Region
  3. 4.2.1 Global Bevacizumab Injection Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Bevacizumab Injection Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Bevacizumab Injection Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Bevacizumab Injection Forecasted Market Size by Region
  7. 4.3.1 Global Bevacizumab Injection Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Bevacizumab Injection Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Bevacizumab Injection Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Bevacizumab Injection by Application
  1. 5.1 Bevacizumab Injection Market by Application
  2. 5.1.1 Age-related macular degeneration (AMD)
  3. 5.1.2 Ovarian Cancer
  4. 5.1.3 Others
  5. 5.2 Global Bevacizumab Injection Market Size by Application
  6. 5.2.1 Global Bevacizumab Injection Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Bevacizumab Injection Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Bevacizumab Injection Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Bevacizumab Injection Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Bevacizumab Injection Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Bevacizumab Injection Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Bevacizumab Injection Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Bevacizumab Injection Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Biocon
  2. 6.1.1 Biocon Company Information
  3. 6.1.2 Biocon Business Overview
  4. 6.1.3 Biocon Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Biocon Bevacizumab Injection Product Portfolio
  6. 6.1.5 Biocon Recent Developments
  7. 6.2 Cadila Pharmaceuticals
  8. 6.2.1 Cadila Pharmaceuticals Company Information
  9. 6.2.2 Cadila Pharmaceuticals Business Overview
  10. 6.2.3 Cadila Pharmaceuticals Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio
  12. 6.2.5 Cadila Pharmaceuticals Recent Developments
  13. 6.3 Centus
  14. 6.3.1 Centus Company Information
  15. 6.3.2 Centus Business Overview
  16. 6.3.3 Centus Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Centus Bevacizumab Injection Product Portfolio
  18. 6.3.5 Centus Recent Developments
  19. 6.4 Dr Reddy's
  20. 6.4.1 Dr Reddy's Company Information
  21. 6.4.2 Dr Reddy's Business Overview
  22. 6.4.3 Dr Reddy's Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Dr Reddy's Bevacizumab Injection Product Portfolio
  24. 6.4.5 Dr Reddy's Recent Developments
  25. 6.5 Genentech
  26. 6.5.1 Genentech Company Information
  27. 6.5.2 Genentech Business Overview
  28. 6.5.3 Genentech Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Genentech Bevacizumab Injection Product Portfolio
  30. 6.5.5 Genentech Recent Developments
  31. 6.6 Hetero Group
  32. 6.6.1 Hetero Group Company Information
  33. 6.6.2 Hetero Group Business Overview
  34. 6.6.3 Hetero Group Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Hetero Group Bevacizumab Injection Product Portfolio
  36. 6.6.5 Hetero Group Recent Developments
  37. 6.7 Samsung Bioepis
  38. 6.7.1 Samsung Bioepis Company Information
  39. 6.7.2 Samsung Bioepis Business Overview
  40. 6.7.3 Samsung Bioepis Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Samsung Bioepis Bevacizumab Injection Product Portfolio
  42. 6.7.5 Samsung Bioepis Recent Developments
  43. 6.8 Amgen
  44. 6.8.1 Amgen Company Information
  45. 6.8.2 Amgen Business Overview
  46. 6.8.3 Amgen Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Amgen Bevacizumab Injection Product Portfolio
  48. 6.8.5 Amgen Recent Developments
  49. 6.9 Bayer
  50. 6.9.1 Bayer Company Information
  51. 6.9.2 Bayer Business Overview
  52. 6.9.3 Bayer Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Bayer Bevacizumab Injection Product Portfolio
  54. 6.9.5 Bayer Recent Developments
  55. 6.10 Pfizer
  56. 6.10.1 Pfizer Company Information
  57. 6.10.2 Pfizer Business Overview
  58. 6.10.3 Pfizer Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Pfizer Bevacizumab Injection Product Portfolio
  60. 6.10.5 Pfizer Recent Developments
  61. 6.11 Eli Lilly
  62. 6.11.1 Eli Lilly Company Information
  63. 6.11.2 Eli Lilly Business Overview
  64. 6.11.3 Eli Lilly Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Eli Lilly Bevacizumab Injection Product Portfolio
  66. 6.11.5 Eli Lilly Recent Developments
  67. 6.12 Roche
  68. 6.12.1 Roche Company Information
  69. 6.12.2 Roche Business Overview
  70. 6.12.3 Roche Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Roche Bevacizumab Injection Product Portfolio
  72. 6.12.5 Roche Recent Developments
  73. 6.13 Mylan
  74. 6.13.1 Mylan Company Information
  75. 6.13.2 Mylan Business Overview
  76. 6.13.3 Mylan Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Mylan Bevacizumab Injection Product Portfolio
  78. 6.13.5 Mylan Recent Developments
7 North America by Country
  1. 7.1 North America Bevacizumab Injection Sales by Country
  2. 7.1.1 North America Bevacizumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Bevacizumab Injection Sales by Country (2021-2026)
  4. 7.1.3 North America Bevacizumab Injection Sales Forecast by Country (2027-2032)
  5. 7.2 North America Bevacizumab Injection Market Size by Country
  6. 7.2.1 North America Bevacizumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Bevacizumab Injection Market Size by Country (2021-2026)
  8. 7.2.3 North America Bevacizumab Injection Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Bevacizumab Injection Sales by Country
  2. 8.1.1 Europe Bevacizumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Bevacizumab Injection Sales by Country (2021-2026)
  4. 8.1.3 Europe Bevacizumab Injection Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Bevacizumab Injection Market Size by Country
  6. 8.2.1 Europe Bevacizumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Bevacizumab Injection Market Size by Country (2021-2026)
  8. 8.2.3 Europe Bevacizumab Injection Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Bevacizumab Injection Sales by Country
  2. 9.1.1 Asia-Pacific Bevacizumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Bevacizumab Injection Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Bevacizumab Injection Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Bevacizumab Injection Market Size by Country
  6. 9.2.1 Asia-Pacific Bevacizumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Bevacizumab Injection Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Bevacizumab Injection Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Bevacizumab Injection Sales by Country
  2. 10.1.1 South America Bevacizumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Bevacizumab Injection Sales by Country (2021-2026)
  4. 10.1.3 South America Bevacizumab Injection Sales Forecast by Country (2027-2032)
  5. 10.2 South America Bevacizumab Injection Market Size by Country
  6. 10.2.1 South America Bevacizumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Bevacizumab Injection Market Size by Country (2021-2026)
  8. 10.2.3 South America Bevacizumab Injection Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Bevacizumab Injection Sales by Country
  2. 11.1.1 Middle East and Africa Bevacizumab Injection Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Bevacizumab Injection Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Bevacizumab Injection Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Bevacizumab Injection Market Size by Country
  6. 11.2.1 Middle East and Africa Bevacizumab Injection Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Bevacizumab Injection Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Bevacizumab Injection Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Bevacizumab Injection Value Chain Analysis
  2. 12.1.1 Bevacizumab Injection Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Bevacizumab Injection Production Mode & Process
  7. 12.2 Bevacizumab Injection Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Bevacizumab Injection Distributors
  10. 12.2.3 Bevacizumab Injection Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst